发生了什么
Biolevate, a Paris-based developer of AI-powered automation software, has raised a €30 million Series A co-led by RAISE France and Orange Ventures. The financing will support Biolevate’s international expansion, accelerate development of its enterprise AI platform, and expand deployments among pharmaceutical and other life sciences organizations.
Biolevate has raised a €30 million Series A co-led by RAISE France and Orange Ventures.
The financing will support Biolevate’s international expansion, accelerate development of its enterprise AI platform, and expand deployments among pharmaceutical and other life sciences organizations.
Biolevate’s platform combines artificial intelligence with scientific evidence, regulatory knowledge, organizational information, and governed workflows to help pharmaceutical and biotechnology companies automate research and administrative activities.
The company’s technology addresses a challenge facing the life sciences industry as organizations seek to accelerate drug discovery, clinical development, and commercialization.
Biolevate aims to reduce the administrative burden on life sciences organizations by automating complex scientific and regulatory processes.
为什么这很重要
Biolevate’s AI-powered automation software aims to reduce the administrative burden on life sciences organizations by automating complex scientific and regulatory processes. The company’s platform combines artificial intelligence with scientific evidence, regulatory knowledge, organizational information, and governed workflows to help pharmaceutical and biotechnology companies automate research and administrative activities.
Biolevate’s AI-powered automation software has the potential to improve scientific research and identify new therapeutic candidates.
The company’s platform can accelerate systematic literature reviews and research synthesis by a factor of 16.
Biolevate’s technology can deliver an 80% efficiency improvement in regulatory intelligence and compliance activities.
The company has established partnerships across the pharmaceutical and technology industries, including relationships with Sanofi, NVIDIA, Microsoft, and regulatory organizations.
Biolevate’s new Boston office will support expansion into the U.S. pharmaceutical market.
互动机制：它实际上是如何运作的
以交互方式探索这一发展背后的基础技术。
Which description best fits "narrow AI", the kind of AI in use today?
接下来看什么
Biolevate’s international expansion, development of its enterprise AI platform, and deployments among pharmaceutical and other life sciences organizations.
Biolevate’s international expansion and development of its enterprise AI platform.
The company’s deployments among pharmaceutical and other life sciences organizations.
Biolevate’s partnerships across the pharmaceutical and technology industries.
The company’s new Boston office and expansion into the U.S. pharmaceutical market.
Biolevate’s plans to double its workforce again over the next 12 months.